甘草和干的开抑制了炎症,并通过向siglec-1来缓解慢性阻塞性肺病中的线粒体功能障碍
Sensen Li1, Juan Cao1, Zhongjie Yang2
1Department of Scientific Research Section, the First People's Hospital of Zhumadian, Affiliated Hospital of Huanghuai University, Zhumadian, Henan 463000, China; Zhumadian Key Laboratory of Chronic Disease Research, School of Medicine, Huanghuai University, Zhumadian, Henan 463000, China.
International immunopharmacology
|December 21, 2024
概括
甘和干生 (LGD) 和其成分甘酸 (GA) 通过向Siglec-1.1,缓解慢性阻塞性肺病 (COPD). 在COPD模型中,这种治疗减少了炎症并改善了线粒体功能.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 慢性阻塞性肺病 (COPD) 是一种严重的呼吸系统疾病,其特征是炎症.
- 甘和干生 (LGD) 是一种具有抗炎功能的中国传统药物.
- 甘氨酸 (GA) 是LGD的关键组成部分,以及Siglec-1,一种在COPD中过度表达的蛋白质,正在研究它们的相互作用.
研究的目的:
- 研究LGD和GA在COPD中的治疗潜力.
- 阐明LGD,GA和Siglec-1在COPD病变发生过程中的相互作用.
- 探索LGD和GA对炎症,线粒体功能和COPD中氧化应激的影响.
主要方法:
- 通过使用香烟烟雾 (CS),脂多糖 (LPS) 和香烟烟雾提取物 (CSE) 建立了COPD大鼠和细胞模型.
- 评估了组织病理变化,炎症性细胞因子水平 (TNF-α,IL-1β,IL-6,IL-8) 和Siglec-1表达.
- 使用高性能液体染色学-并联质谱法 (HPLC-MS) 来确认GA-Siglec-1结合. 还评估了线粒体功能和反应性氧物种 (ROS) 生产.
主要成果:
- 在COPD小鼠中,LGD治疗显著降低了肺损伤和炎症,并在细胞模型中抑制了炎症性细胞因子.
- 在LGD治疗后,Siglec-1表达,由CS升高,下降.
- 证实GA针对Siglec-1,调节炎症反应,减少ROS产量和线粒体功能障碍,从而抑制COPD的进展.
结论:
- 通过其成分GA,LGD有效地准Siglec-1,以抑制COPD中的炎症.
- 治疗LGD可以缓解线粒体功能障碍和氧化应激,这是COPD进展的关键因素.
- 这些发现强调了LGD作为一种潜在的治疗策略,通过调节Siglec-1通路来管理COPD.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
177
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
177
01:17Drugs Used in Lower Respiratory Disorders: Overview
349
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
349
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:21Drugs for Treatment of Constipation-Predominant IBS
133
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
133